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Abstract
Lung cancer and pulmonary tuberculosis (TB) are highly prevalent and representing major public health issues. They share com-
mon risk factors and clinical manifestations. It is also suggested that TB predicts raised lung cancer risk likely related to chronic 
inflammation in the lungs. However, it does not seem to influence the clinical course of lung cancer provided that it is properly 
treated. We present a case report of a 57-year old male with concurrent TB and lung cancer. He was diagnosed with positive 
sputum smear for acid fast bacilli (AFB) and subsequent culture of Mycobacterium tuberculosis. Besides, his comorbid conditions 
were chronic hepatitis C virus (HCV) infection and peripheral artery disease (PAD). Later while on anti-tuberculous treatment (ATT) 
squamous cell lung cancer (SCC) was confirmed with computed tomography (CT) guided biopsy. Due to poor general condition 
the patient was not fit for either surgery or radical chemo- and radiotherapy. He was transferred to hospice for palliative therapy. 
We want to emphasize that both TB and lung cancer should be actively sought for in patients with either disorder. In addition, 
there is no doubt that these patients with lung cancer and with good response to TB treatment should be promptly considered 
for appropriate anticancer therapy. 
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Case report
The interaction between lung cancer and 
tuberculosis (TB) has been long established [1]. 
There is good evidence that preexisting TB is in-
dependently associated with an increased risk of 
lung cancer [2]. Besides, solid-organ malignancy 
raises the likelihood of TB reactivation particu-
larly in patients with old healed TB lesions [3]. 
A 57-year old severe underweight (body-
mass-index (BMI) 15 kg/m2) male was admitted to 
a respiratory ward with a history of 3-week long 
anorexia, fatigue, purulent cough and 1-month 
long fever. His cough started 6 months before. 
He reported significant weight loss of 15 kilos for 
6 months. He had no chest pain and haemopty-
sis. As an out-patient he received the course of 
amoxicillin with clavulanic acid with short-lived 
improvement. Also, the patient complained of 
intermittent claudication after a short walking 
distance. He was a resident of the shelter for 
homeless for a few years. His primary profession 
was a garage worker whereas his most recent oc-
cupation was garbage sorting. There was a history 
of heavy smoking (30-pack years) and alcohol 
addiction. He had not been drinking for last 2 
years. He had no evident contact with a confirmed 
TB source. In the distant past he underwent an 
ear-nose-throat operation for the nose deformity. 
On examination, he was undernourished, nor-
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motensive (blood pressure — 110/70 mm Hg), 
non-tachycardic (85/min), slightly tachypneic 
(16/min) with diminished breath sounds over 
the left lower lobe. There was moderate pitting 
oedema of both his legs and worse peripheral 
circulation in his left foot. His chest X-ray showed 
irregular consolidation in the upper left lobe and 
large mass in the lower left lobe (Fig. 1). In the 
bronchoscopy there were no abnormalities apart 
from purulent secretions. Computed tomogra-
phy (CT) of the chest revealed multiple nodules 
with poorly defined margins in peribronchial 
distribution in both upper lobes, irregular con-
solidations and cavities in the upper left lobe. CT 
showed also a round contrast-enhanced mass in 
the left lower lobe measuring 92 × 76 mm with 
a thick-walled cavity with no hilar and medi-
astinal lymphadenopathy (Fig. 2). Abdominal 
ultrasound did not show any abnormality. The 
inflammatory markers were raised (C-reactive 
protein 100 mg/L, white blood count (WBC 22 
G/L). On admission his haemoglobin was low 
(9.9 g/L) as well as albumin (23 g/L). His sputum 
smear was positive for acid-fast bacilli (AFB) 
(++). Anti-hepatitis C virus (HCV) antibodies 
were detected through ELISA method. He tested 
negative by ELISA for human immunodeficiency 
virus (HIV) and hepatitis B surface antigen (HB-
sAg). Consequently, the patient was transferred 
to the tuberculosis ward. Anti-tuberculous treat-
ment (ATT) was started with rifampicin (R), iso-
niazid (H), ethambutol (E) and pyrazinamide (Z). 
Mycobacterium tuberculosis was cultured and 
identified with MGIT (Mycobacteria Growth In-
dicator Tube). Drug susceptibility testing (DST) 
proved sensitivity to the all first-line drugs. Later 
while on ATT persistent severe pain developed 
in his left lower limb. He was transferred to 
a vascular surgery ward with the diagnosis of 
chronic critical leg ischaemia. CT angiography 
confirmed significantly occluded left popliteal 
and left iliac internal arteries with the collateral 
flow. The patient declined any endovascular 
treatment and was admitted again to the TB ward. 
Peripheral artery disease (PAD) was managed 
with aspirin, statin and strict blood pressure 
control. Whilst continuing ATT the CT guided 
biopsy of lung mass confirmed squamous cell 
carcinoma with positive staining for CK-7 and 
p63 whereas negative for TTF1. Both routine 
staining and immunohistochemistry were neces-
sary for a precise diagnosis. His clinical staging 
was T3N0M0. His general condition deteriorated 
with further weight loss. Eastern Cooperative 
Oncology Group performance status was 3 which 
Figure 1. Chest X-ray on admission. Numerous ill-defined consoli-
dations in the upper left lobe. An oval mass measuring 85 mm in the 
lower left lobe behind the heart
Figure 2. Chest CT. A large oval irregular mass in the lower left lobe 
with the contrast enhancement
precluded him from any anticancer treatment. 
Besides he refused any referral to an oncologist. 
After 2 months well-tolerated ATT was continued 
only with HR with good radiological response but 
with an increase of the lung mass (Fig. 3). Sputum 
samples were positive for AFB after 2 months but 
converted to negative later after another 1 month. 
There was persistently elevated WBC (27 g/L, 
differential: band cells 2%, segmented neutro-
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during 5 years after TB diagnosis, the overall risk 
remained still increased 2-fold for 20 years. Con-
sequently, this relationship does not seem to be 
affected by the early symptoms bias when the first 
lung cancer symptoms can be wrongly attributed 
to apparent TB. Zheng et al. found that the odds 
ratio (OR) for lung cancer associated with former 
TB was 1.5 (95% CI: 1.2−1.8) [7]. Likewise, it was 
most elevated after 10 and more years after TB 
infection (aOR 2.8, 95% CI:1.6−5.0). 
TB appears to affect the lung cancer mortali-
ty. It remained an independent predictor of lung 
cancer death (aHR 2.01, 95% CI: 1.4−2.9) [8]. 
There was no TB association with other malignan-
cies, both related and non-related to smoking. 
Patients with TB diagnosed before or together 
with lung cancer had worse prognosis than those 
with no TB at the diagnosis of lung cancer [9]. 
In contrast, in one retrospective review TB im-
proved median survival especially in SCC (11.6 
vs 8.8 months, p < 0.01) [10]. This phenomenon 
could be explained by the effective T cell immu-
nity nearby tumor. Finally, the only independent 
prognostic factors for non-localized disease ap-
peared to be its stage and treatment but not any 
comorbidity such as TB [11].
Alternatively, it is recognized that cancer 
patients have higher incidence of tuberculosis. 
In the retrospective cohort study of cancer pa-
tients aHR for TB was 1.67 (95% CI:1.42−1.96) 
[12]. The highest incidence rate ratio (IRR) of 
TB was among oesophagus, oral, lung cancers 
(respectively: 6.4, 3.5 and 2.8) and haematological 
malignancies (IRR 3.0). In a prospective observa-
tion that risk for TB in patients with solid-organ 
malignancy was over 4.5 times higher compared 
with non-malignant group [3]. That risk was 
especially elevated in patients with old healed 
TB and concurrent chemotherapy. 
The explanation of that association is far 
from clear. Lung cancer may develop autonomo-
usly and weaken the local immunity which may 
result in latent TB reactivation or new exogenous 
infection. Yet chronic inflammatory response in 
TB with extensive remodeling of lung tissue may 
serve as a source of malignancy. That is suppor-
ted by long-lasting observation of scar cancer. 
Furthermore, the laterality of TB and lung cancer 
was considerably correlated [7]. It was also recen-
tly shown that chronic TB infection causes cell 
dysplasia and SCC [13]. Mycobacterium infected 
macrophages play a key role in TB induced carci-
nogenesis by causing DNA damage. These expe-
rimental findings confirm a causal link between 
TB and malignant transformation. 
Figure 3. Chest X-ray in the 5th month of ATT. Partial resolution of the 
consolidations in the left upper lobe. Progression of an oval mass in 
the left lower lobe 
phils 86%, lymphocytes 11% and monocytes 1%). 
Due to steady decline in haemoglobin altogether 
4 units of packed red cells were transfused. Despite 
lung cancer progression he did not complained of 
any chest pain, haemoptysis and dyspnoe. When 
the patient became bedridden he was admitted to a 
hospice for palliative care. After a few days he died. 
Discussion
We present a case of concurrent lung cancer 
and pulmonary tuberculosis in a heavy-smoking 
male. Such a cluster in an underweight patient 
could be a plain coincidence. However, there is 
robust evidence highlighting the role of chronic 
inflammation in the pathogenesis of lung cancer. 
Both these diseases have an enormous public he-
alth impact. In 2013 9.0 million people developed 
TB and 1.5 died form this infection [4]. Whereas 
in 2012 lung cancer was diagnosed in nearly 1.83 
million cases and 1.59 died from it [5]. Globally 
lung cancer is the largest contributor to new can-
cer diagnoses and to death from cancer. 
In a cohort study adjusted for comorbidities 
hazard ratio (aHR) for lung cancer in TB patients 
was 3.32 (95% CI: 2.70−4.09) [2]. The incidence 
of lung cancer was 11-fold higher than in nontu-
berculosis subjects. In recent systematic review 
the independent association between lung cancer 
and previous TB was confirmed (RR 3.43; 95% 
CI: 1.93−6.11) [6]. Although the highest risk was 
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 The clinical course of TB in lung cancer is 
not very unusual. There is no doubt that respira-
tory TB if treated appropriately does not affect the 
clinical course of lung cancer. In a retrospective 
case-control there was no difference in duration 
of symptoms between TB group with and without 
malignancy [14]. There was no difference in CT 
responses to treatment as well as the morphologic 
features, either. Hence, the overlapping symp-
toms, radiological similarities and clinical bias 
for TB, especially in high-burden TB countries, 
may result in clinical errors and undue delay in 
correct diagnosis of lung cancer. Therefore every 
newly TB diagnosed patient and particularly tho-
se with suspected relapse or poor response should 
be carefully evaluated for coexisting malignancy. 
On the other hand, during the follow-up new lung 
lesions especially in a tree-in-bud appearance 
may be suggestive of active TB [14].
There are conflicting reports on histological 
subtype of lung cancer associated with TB. In 
a large retrospective observation SCC was found 
in over 50% cases of TB and concurrent lung 
cancer [15]. These patients with old TB lesions 
and SCC had worse prognosis compared to those 
without TB lesions [16]. Conversely, Liang et al. 
found that only adenocarcinoma was significantly 
associated with TB [6]. Nevertheless, very recent 
study revealed that the predominant type was 
still SCC [17]. Though it depends on the regional 
distribution of lung cancer histology it is rather 
SCC which is more frequent in TB patients. 
While treating those patients the method 
of choice is the surgery [15]. Patients with more 
advanced stages of malignancy can be treated 
with both chemotherapy and ATT [18]. In pa-
tients with TB detected during anticancer the-
rapy or shortly after there were no differences 
in clinical outcomes. All fatal courses were due 
to progression of the underlying malignancy but 
not TB itself. However, these patients underwent 
cyclic chemotherapy with no significant nutritional 
deficiency and modest immunosuppression. Our 
patient died due to lung cancer progression while 
he had a fairly good response to ATT. Therefore 
chemotherapy is not an obstacle in treating TB [18].
Our patient had comorbidities such as chro-
nic HCV infection and PAD. In Georgia with high 
TB-burden HCV infection was much more preva-
lent among TB patients compared with hepatitis 
B infection or HIV infection (respectively, 21%, 
4.3% and 1.8%) [19]. It is also noteworthy that 
HCV co-infection was not associated with severe 
drug-induced hepatotoxicity [19]. Indeed, our pa-
tient tolerated ATT quite well. PAD in a heavy smo-
king patient with TB might be a common clinical 
presentation. Moreover, there has been established 
genetic link between smoking quantity, nicotine 
dependence, the risk of PAD and lung cancer [20]. 
There is little doubt about the association be-
tween TB and lung cancer. They share risk factors 
such as smoking, alcoholism, chronic obstructive 
pulmonary disease and immunosuppression. TB 
may raise the lung cancer risk through chronic 
inflammation both locally and systematically. 
Also, malignancy may impair infection barriers 
making patients more susceptible to TB. The lat-
ter may serve as a marker of occult lung cancer. 
Alternatively, TB may mimic other diseases like 
lung cancer and pulmonary infarction [21]. Then 
the correct diagnosis in patients with active TB 
may be challenging. Increased long-term risk of 
cancer in these patients suggests that it is rather 
TB which promotes malignancy development. Fi-
nally, there is clear evidence that concurrent and 
treated properly TB does not affect lung cancer 
course and prognosis. 
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